Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

by Shiming Ye, Melvin I. Fox, Nicole A. Belmar, Mien Sho, Debra T. Chao, Donghee Choi, Yuni Fang, Vivian Zhao, Stephen F. Keller, Gary C. Starling, Patricia A. Culp
Published 2017-01-01

Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR

by James W. Purcell, Han K. Kim, Sonia G. Tanlimco, Minhtam eDoan, Melvin eFox, Peter eLambert, Debra T. Chao, Mien eSho, Keith E. Wilson, Gary C. Starling, Gary C. Starling, Patricia A. Culp
Published 2014-01-01

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

by Ludmilla de Plater, Anne Vincent-Salomon, Frédérique Berger, André Nicolas, Sophie Vacher, Eléonore Gravier, Aurélie Thuleau, Narjesse Karboul, Marion Richardson, Clément Elbaz, Elisabetta Marangoni, Ivan Bièche, Xavier Paoletti, Sergio Roman-Roman, Patricia A Culp, Bernard Asselain, Véronique Diéras, Didier Decaudin
Published 2014-01-01